Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes

PHASE3CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

March 31, 2006

Study Completion Date

December 31, 2006

Conditions
MeaslesMumpsRubellaVaricella
Interventions
BIOLOGICAL

MeMuRu-OKA (study vaccine)

Trial Locations (20)

35390

GSK Investigational Site, Giessen

37269

GSK Investigational Site, Eschwege

54290

GSK Investigational Site, Trier

54294

GSK Investigational Site, Trier

55127

GSK Investigational Site, Mainz

55131

GSK Investigational Site, Mainz

55543

GSK Investigational Site, Bad Kreuznach

67227

GSK Investigational Site, Frankenthal

67547

GSK Investigational Site, Worms

68167

GSK Investigational Site, Mannheim

70469

GSK Investigational Site, Stuttgart

74357

GSK Investigational Site, Bönnigheim

74523

GSK Investigational Site, Schwäbisch Hall

75015

GSK Investigational Site, Bretten

76189

GSK Investigational Site, Karlsruhe

77654

GSK Investigational Site, Offenburg

77694

GSK Investigational Site, Kehl

77704

GSK Investigational Site, Oberkirch

77955

GSK Investigational Site, Ettenheim

97941

GSK Investigational Site, Tauberbischofsheim

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY